Detection of Low Molecular Weight Derivatives of Cyclin E1 Is a Function of Cyclin E1 Protein Levels in Breast Cancer
Open Access
- 15 July 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (14) , 7355-7360
- https://doi.org/10.1158/0008-5472.can-05-3240
Abstract
Cyclin E1 regulates the initiation of the S phase program in the mammalian cell division cycle. In normal cells, cyclin E1 protein expression is tightly controlled through a combination of transcriptional and proteolytic regulatory processes. However, in many types of human tumor, cyclin E1 expression is frequently dysregulated, including overexpression, nonperiodic expression relative to cell division, and generation of low molecular weight (LMW) derivatives. LMW derivatives of cyclin E1 have been proposed to be generated by the in vivo proteolytic cleavage of the full-length cyclin E1 protein by a yet to be identified tumor-specific protease. Recently, it was suggested that overexpression of full-length or LMW derivatives of cyclin E1 are independent variables associated with poor outcome in patients with breast cancer. However, we have extensively analyzed cyclin E1 protein expression in primary breast tumors and breast tumor-derived cell lines and found that the ability to detect LMW derivatives of cyclin E1 correlates only with the level of cyclin E1 protein. When cyclin E1 levels on Western blots are normalized, LMW derivatives of cyclin E1 were observed at roughly equal levels in all primary breast tumors, breast tumor-derived cell lines, immortalized nontransformed human mammary epithelial cells, and normal breast tissue. Therefore, the detection of LMW derivatives of cyclin E1 is likely a function of cyclin E1 protein levels, and the activity of the proteolytic machinery responsible for their generation is not a tumor-specific property. (Cancer Res 2006; 66(14): 7355-60)Keywords
This publication has 29 references indexed in Scilit:
- Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast CancerCancer Research, 2004
- Cyclin E deregulation alters the biologic properties of ovarian cancer cellsOncogene, 2004
- Inactivation of hCDC4 can cause chromosomal instabilityNature, 2004
- Activation of Cyclin-dependent Kinase 2 by Full Length and Low Molecular Weight Forms of Cyclin E in Breast Cancer CellsJournal of Biological Chemistry, 2004
- Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancerOncogene, 2003
- p16INK4a inactivation is not required to immortalize human mammary epithelial cellsOncogene, 2002
- Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancerEuropean Journal of Surgical Oncology, 2001
- Cdk2-dependent and -independent Pathways in E2F-mediated S Phase InductionJournal of Biological Chemistry, 2000
- Cyclin E: in mid-cycleBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1996
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958